Excitant Therapeutics LLC
Edmond, OK
- UEI
- LLKQBSKXYLM8
- CAGE
- 829C5
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- Enterprise Square, 2501 E Memorial Rd, Edmond, OK 73013, USA
- Website
- excithera.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Retina Consultants Of Texas | Bellaire, TX | — |
| Nanoscope Technologies LLC | Bedford, TX | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Human Cell Co | Naperville, IL | — |
| Amydis, Inc. | San Diego, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Administration | Pasadena, CA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Excitant Therapeutics LLC is an Oklahoma City-based pharmaceutical startup focused on preclinical ophthalmic research and the development of novel small molecule drugs for age-related macular degeneration (AMD), diabetic retinopathy (DR), and other retinal diseases.
Through prime federal grant awards from the National Institutes of Health National Eye Institute, Excitant Therapeutics has conducted research and development of lead compound A190 as an oral treatment targeting multiple pathogenic factors involved in AMD and DR. Specific services provided through these grants include preclinical efficacy studies of A190 in animal models of neovascularization, vascular leakage, oxidative stress, and inflammation associated with AMD and DR; pharmacokinetic testing and ocular biodistribution studies of A190; investigational new drug application-enabling toxicity studies in multiple species; and early phase mechanism of action and dose optimization studies. In addition to internal R&D activities, Excitant Therapeutics has partnered with academic institutions on NIH subawards to evaluate the therapeutic potential of A190 and earlier lead PPAR-alpha agonists for treating retinal inflammation and vascular permeability in preclinical AMD and DR studies.
Quick answers
Is Excitant Therapeutics LLC registered in SAM.gov?
Yes. Excitant Therapeutics LLC's SAM.gov registration is active through June 15, 2027.
What is Excitant Therapeutics LLC's most recent federal award?
Excitant Therapeutics LLC's most recent federal grant award is A novel small molecule for the prevention and treatment of age-related macular degeneration (R43EY033247), from National Eye Institute (NIH), on September 1, 2021.
On GovTribe
See Excitant Therapeutics LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors